USV, Biogenomics launch INSUQUICK, biosimilar Insulin Aspart for diabetes treatment
Insuquick will be available in cartridges, vials, and prefilled disposable pens
USV and Biogenomics announced the launch of INSUQUICK, biosimilar Insulin Aspart.
A company statement informed, “InsuQuick is a “Make in India” product, developed and manufactured using 100 per cent indigenous technology, and has undergone a robust clinical program to ensure global quality standards. It is available in all metros, and Tier I/II cities.”
Insuquick will be available in cartridges, vials, and prefilled disposable pens, offering flexibility tailored to the needs of people with diabetes.
- Advertisement -